Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Reverence Enterprises, LLC: $7.0M upfront; up to $1.0M event-based milestones
Indications
Prostate cancer(Stage not disclosed)
Status note 10-Q calls ABO-701 a recently licensed engineered T-cell therapy targeting PSMA for prostate cancer and separately describes the March 18, 2026 Reverence license for the PSMA SIR-T autologous T-cell product (IND to be filed, Phase 1 study planned); the filing does not state ABO-701 and the SIR-T product are the same candidate. Indication stage pending IND.
X-linked retinoschisis (XLRS)(Stage not disclosed)
Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). 10-K: pre-IND meeting April 2023; animal efficacy/toxicology and cGMP manufacturing postponed to 2026. Beacon Therapeutics out-licenses the AAV204 capsid for select ophthalmology targets (upfront + milestones + tiered royalties).
Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). 10-K: pre-IND meeting June 2023.
ABO-505
Preclinical · ActiveModality: AAV gene therapy (Opa1 delivered via AAV204)
Target Opa1
Indications
Autosomal dominant optic atrophy (ADOA)(Stage not disclosed)
Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). Para-retinal injection; preclinical only per 10-K.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.